TITLE

The Role of Tegafur/Uracil in Pulmonary Malignancy

AUTHOR(S)
Langer, C.J.
PUB. DATE
December 1999
SOURCE
Drugs;Dec1999 Supplement 3, Vol. 58 Issue 6, p71
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Tegafur/uracil (UFT) is an oral fluorinated pyrimidine composed of a combination of uracil and tegafur in a 4 : 1 molar ratio. When given on a continuous basis, it yields a fluorouracil area under the concentration-time curve identical to that achieved with isomolar concentrations of fluorouracil administered by continuous infusion. Its 8.7% response rate in advanced non-small cell lung cancer (NSCLC) is modest, but it has demonstrated synergy with cisplatin in human solid tumour xenografts. In combination with cisplatin in patients with advanced NSCLC, response rates of 29 to 43% were observed with acceptable toxicity. Researchers in Japan have demonstrated the utility of this agent as adjuvant therapy after surgical resection, either alone or in combination with cisplatin and vindesine versus observation; long term survival rates exceed 60%, compared with 49% for the control group. Efforts in the US will assess the role of this agent as non-cross-resistant consolidation therapy after a plateau in response has been obtained with platinum-based therapy in advanced disease. They will also recapitulate the Japanese studies, assessing their utility as adjuvant therapy in NSCLC patients who have undergone resection. Finally, ongoing phase I studies are combining this agent with paclitaxel and other systemic agents.
ACCESSION #
9593661

 

Related Articles

  • Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment. Tokalov, Sergey V.; Abolmaali, Nasreddin D. // BMC Cancer;2010, Vol. 10, p57 

    Background: Mutations within the tumor suppressor TP53 gene are one of the most common genetic alterations present at high frequency in human tumors and have been shown to be associated with resistance to radiochemotherapy. The lack of the wild type TP53 gene in cancer cells could be exploited...

  • Uracil-Tegafur as Adjuvant Chemotherapy in Lung Cancer. Zepf, Bill // American Family Physician;1/1/2005, Vol. 71 Issue 1, p185 

    Presents information on a study which dealt with the use of uracil-tegafur (UFT) for adjuvant chemotherapy in lung cancer. Description of uracil-tegafur; Findings from trials of UFT for non-small-cell lung cancer; Exclusion criteria in using UFT.

  • Uracil-Tegafur as Adjuvant Chemotherapy in Lung Cancer. Zepf, Bill // American Family Physician;1/1/2005, Vol. 71 Issue 1, p185 

    Presents information on a study which dealt with the use of uracil-tegafur (UFT) for adjuvant chemotherapy in lung cancer. Description of uracil-tegafur; Findings from trials of UFT for non-small-cell lung cancer; Exclusion criteria in using UFT.

  • The Role of Chemotherapy and Radiation in the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC). Wagner, Timothy D.; Yang, Gary Y. // Current Drug Targets;Jan2010, Vol. 11 Issue 1, p67 

    No abstract available.

  • Synthesis of 4-(3,4-dicarboxamido-1H-pyrrole)pyrimidines as Anaplastic Lymphoma Kinase Inhibitors. Byung Jin Byun; Latif, Muhammad; Kwangho Lee // Bulletin of the Korean Chemical Society;Feb2015, Vol. 36 Issue 2, p520 

    To explore non-aniline aromatic substitution on the pyrimidine C4 position, novel 4-(N,N'-di-n-propyl-3,4dicarboxamido-1H-pyrrole)pyrimidines are designed and synthesized as anaplastic lymphoma kinase inhibitors for non-small cell lung cancer treatment. To overcome the unexpected cleavage...

  • uracil (U):. Schlegel, Rolf H. J. // Encyclopedic Dictionary of Plant Breeding & Related Subjects;2003, p426 

    An encyclopedia entry for uracil is presented, which refers to a pyrimidine base that occurs in RNA.

  • A randomized phase III trial of adjuvant treatment for resected non-small cell lung cancer in Japan. Ichinose, Yukito // Cancer Chemotherapy & Pharmacology. Supplement;Dec2006, Vol. 58, p43 

    Two randomized phase III trials [uracil–tegafur (UFT) and bestatin trials] of adjuvant treatment for resected stage I non-small cell lung cancer (NSCLC) have recently been completed in Japan. The Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy conducted a phase III...

  • The Role of Pemetrexed Combined with Gemcitabine for Non-Small-Cell Lung Cancer. Ngeow, Joanne; Chee-Keong Toh // Current Drug Targets;Jan2010, Vol. 11 Issue 1, p61 

    No abstract available.

  • Foreword.  // Current Medical Literature: Lung Cancer;2012, Vol. 5 Issue 3, preceding p65 

    An introduction to the journal is presented wherein the author discusses advances in the treatment of lung cancer and introduces review articles published within the issue.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics